Gamma auditory stimulation device (active setting): Participants will receive auditory stimulation using the gamma auditory stimulation device (active setting) for 1 hour per day, 5 days a week, over 12 weeks, for a total of 60 hours.
Gamma auditory stimulation device (sham setting): Participants will receive auditory stimulation using the gamma auditory stimulation device (sham setting) for 1 hour per day, 5 days a week, over 12 weeks, for a total of 60 hours.
Study summary
Animal studies have shown that 40 Hz auditory stimulation alone can improve spatial memory and reduce Aβ deposition. However, human studies using 40 Hz auditory stimulation alone remain limited. Therefore, this study will use a randomized, double-blind, placebo-controlled design to investigate the effects of 40 Hz auditory stimulation on cognitive function, EEG activity, sleep quality, and quality of life in older adults with mild cognitive impairment (MCI) or mild dementia.
Eligibility
Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Age over 60 years old.
2. MMSE≤ 24
3. CDR scores of 0.5 and 1
4. Voluntary to sign the Informed Consent Form.
Exclusion Criteria:
1. Diagnosis of other psychiatric or neurological disorders
2. Drug or alcohol addictions.
3. Serious heart, liver or kidney disorders, and visual, auditory or motor impairments interfering with neuropsychological tests.
4. History of clinical stroke, major depressive disorder or dysthymic disorder according to the DSM-5.
Primary outcome measure(s)
Changes in neurophysiological function. — baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3) The changes of power spectral density (PSD), response to gamma auditory stimulation and functional connectivity (FC) at each frequency band will be analyzed by EEG data from each subject.
Trial sites (1)
Facility
City
Region
Status
Chang Gung University
Taoyuan
Guishan
Recruiting
More Chang Gung Memorial Hospital trials in Taiwan
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
